Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 8/20 | 0.34 |
| ▸ | CTSD | P07339 | 7/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.34 |
| ▸ | TK2 | O00142 | 2/20 | 0.34 |
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560418 | 0.86 | ADORA1 (0.40) | TK1HTTMETDRD1KMO | |
| SCHEMBL14396457 | 0.86 | TK1 (0.35) | TK1HTTMETTK2DRD1 | |
| SCHEMBL3568995 | 0.84 | MET (0.37) | TK1HTTMETDRD1 | |
| SCHEMBL3554398 | 0.82 | HTT (0.35) | TK1HTTMETTK2 | |
| SCHEMBL3562463 | 0.81 | HTT (0.34) | TK1HTTMETDRD1 | |
| SCHEMBL3559062 | 0.81 | MET (0.37) | TK1HTTMETTK2 | |
| SCHEMBL3567537 | 0.81 | TNKS (0.41) | TK1HTTTK2GRIA2GSK3B | |
| SCHEMBL3561317 | 0.80 | TK2 (0.38) | TK1TK2USP1KMOPRKCB | |
| SCHEMBL3568151 | 0.77 | TK1 (0.35) | TK1HTTMETTK2 | |
| SCHEMBL3568177 | 0.76 | HTT (0.38) | TK1HTTMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007750-B1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| US-7727988-B2 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2010-06-01 | — | — | US | disclosed |
| EP-2007750-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | EP | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | GLAXO GROUP LIMITED (GB) | 2007-10-25 | — | — | US | disclosed |
| WO-2007113232-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113232-A1 | AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249642-A1 | Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione | AZI2, NT5C3B, CYP1B1 | TK1 386/4885HTT 2295/4885MET 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.